Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human Fc gamma RIIIB /CD16b Protein, His Tag (SPR & BLI & MALS verified), 1mg  

Recombinant human Fc gamma RIIIB /CD16b Protein, His Tag (SPR & BLI & MALS verified), 1mg

Recombinant Human Fc gamma RIIIB / CD16b (NA2), His Tag (CDB-H5222) is expressed from human 293 cells (HEK293), His Tag (SPR & BLI & MALS verified)

Synonym
recombinant, human, protein Fc gamma RIIIB, CD16b (NA2), FCGR3B, CD16B, FCG3B, FCGR3, FCG3, IGFR3, FCGR-3, FCG-3, IGFR-3, Fcr, Fcgr, Fc receptor, Fc gamma receptor

More details

CDB-H5222-1K

Availability: within 7 days

2 200,00 €

Background
CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages. CD16B also kown as FCGR3B and FCG3B, is expressed specifically by polymorphonuclear leukocytes (neutrophils) and stimulated eosinophils. CD16B is the low affinity receptor for the Fc region of immunoglobulins gamma. FCGR3B binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, FCG3B is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. CD16B may serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.

Source
Recombinant Human CD16b (NA2), His Tag (CDB-H5222) is expressed from human 293 cells (HEK293). It contains AA Gly 17 - Ser 200 (Accession # O75015-1). The NA1 form of the CD16b differ with the NA2 form of CD16b in AA36, 65, 82, and 106. The NA1 form carries R36, N65, D82, and V106, while the NA2 form carries S36, S65, N82, and I106.
Predicted N-terminus: Gly 17

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 22.7 kDa. The protein migrates as 38-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.
 
Bioactivity
Please refer to product data sheet. 

Use BIAFFINS FcyR BINDING ASSAYS for detailed kinetic analysis of your antibodies using SPR.

Figure: Real-time kinetic analysis of FcγRIIIb binding to antibody using surface plasmon resonance.

Clinical and Translational Updates

(1) "Characterization of human FCGR3B*02 (HNA-1b, NA2) cDNAs and IMGT standardized description of FCGR3B alleles"
Bertrand, Duprat, Lefranc et al
Tissue Antigens (2004) 64 (2), 119-31
(2) "Gene frequencies of human neutrophil antigens in the Tunisian blood donors and Berbers"
Abid, Zili, Bouzid et al
Tissue Antigens (2001) 58 (2), 90-2
(3) "Ligand binding and phagocytosis by CD16 (Fc gamma receptor III) isoforms. Phagocytic signaling by associated zeta and gamma subunits in Chinese hamster ovary cells"
Nagarajan, Chesla, Cobern et al
J Biol Chem (1995) 270 (43), 25762-70
Showing 1-3 of 3 papers.
Please refer to product data sheet.